Temozolomide in children with progressive low-grade glioma

We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma. Thirty eligible patients were enrolled on this study. Median age at enrollment was 10 years (range, 4–18 years). Eligible patients received TMZ (200 mg/m(2) per day) by mout...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gururangan, Sridharan, Fisher, Michael J., Allen, Jeffrey C., Herndon, James E., Quinn, Jennifer A., Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Phillips, Peter C., Watral, Melody A., Krauser, Jeanne M., Friedman, Allan H., Friedman, Henry S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Duke University Press 2007
Schlagworte:
Special Focus: Pediatric Neuro-Oncology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC1871667/
https://ncbi.nlm.nih.gov/pubmed/17347491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2006-030
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge